尔康制药股票讨论区

Investors may believe the company's moderate P/S ratio and benign revenue growth rate might not outperform the industry. Continuation of recent medium-term revenue trends could risk a share price decline, endangering shareholders' investments.

The declining revenue has led to the underperformance of the company's stock. The CEO's modest pay and uncertain future earnings growth reflect the market's negative sentiment towards the stock, leading to a 3% per year loss over the past five years.